Clinical trials: Upper Extremity Orthopedic Surgery Patients
- Condition Upper Extremity Orthopedic Surgery Patients
- Funder type Industry (pharma, biotech, devices)
Venous Thromboembolism
Dose Ranging Study in Elective Total Hip Replacement Surgery
The primary objective is to: demonstrate the efficacy of SR123781A in the prevention of venous thromboembolism (VTE) by the demonstration of a dose-response in patients undergoing total hip replacement surgery.
- Trial name
- DRIVE (NCT00338897)
- Testing
- SR123781A
- Where
- 14 sites in Argentina, Bulgaria and 12 more
- Volunteers
- 1,090 people
- Sponsor
- Sanofi
Postoperative Pain
Maxigesic® IV Phase 3 Exposure Study
The study aims to determine the tolerability of repeated doses of Maxigesic® IV over an extended period of exposure.
- Trial name
- NCT04005755
- Testing
- Maxigesic® IV
- Where
- 4 sites in United States, New Zealand
- Volunteers
- 232 people
- Sponsor
- AFT Pharmaceuticals, Ltd.
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
The primary objective was to demonstrate the dose-response of Semuloparin sodium (AVE5026) for the prevention of Venous Thromboembolism [VTE] in patients undergoing total knee replacement [TKR] surgery.
- Trial name
- TREK (NCT00331838)
- Testing
- Semuloparin sodium, Enoxaparin sodium
- Where
- 19 sites in Argentina, Bulgaria and 17 more
- Volunteers
- 705 people
- Sponsor
- Sanofi